The established and US-market leading MODULITH SLX-F2 extracorporeal shock wave lithotripter from STORZ MEDICAL has recently received the FDA 510 (k) clearance for new indications. With this clearance, an absolutely unique selling point for STORZ MEDICAL is that children over the age of three years suffering of stone disease can now be treated non-invasively^{(*1,2, 3)}. The MODULITH SLX-F2 is the first and the only lithotripter available for lithotripsy in children in the USA.